ALXO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ALX Oncology Holdings Inc (ALXO) is not a strong buy for a beginner investor with a long-term focus and $50,000-$100,000 to invest. The stock lacks immediate positive catalysts, exhibits weak technical indicators, and has poor financial performance. Insider selling and no recent congress trading data further detract from its attractiveness. While analysts have optimistic long-term price targets, the lack of near-term growth and significant risks make it better to hold off on investing at this time.
The MACD is negatively expanding, RSI is neutral at 36.923, and moving averages are converging, indicating no clear trend. The stock is trading near its support level of 1.987, with resistance at 2.231. Overall, the technical indicators suggest a weak or uncertain trend.
and see potential in ALX Oncology's CD47 combo program for metastatic breast cancer, which could deliver results in mid-2027.
Insider selling has increased by 2135% over the last month, and there are no significant hedge fund trading trends. Financial performance is weak, with a net income drop of -21.65% YoY and an EPS decline of -22.22% YoY. No recent news or congress trading data is available.
In 2025/Q4, revenue remained at $0 with no growth YoY. Net income dropped to -$22.85M (-21.65% YoY), and EPS fell to -0.42 (-22.22% YoY). Gross margin remained at 0 with no improvement.
Analysts have given Buy or Overweight ratings with price targets ranging from $4 to $6. They are optimistic about the company's CD47 combo program and its potential to deliver strong results in mid-2027. However, the next major catalyst is not expected until the second half of 2026.
